The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...

The combination of belrestotug and dostarlimab significantly improved response rates in patients with previously untreated ...

High response rates reported by GSK and iTeos at the 2024 European Society for Medical Oncology Congress offer a ray of light ...

The published belrestotug/dostarlimab data is still too immature to prove the combination’s capability to disrupt the NSCLC ...

The results of the GALAXIES Lung-02 study reported at the ESMO congress in Barcelona showed that the drug – added to GSK's PD ...

Teos Therapeutics' belrestotug shows promising response rates in lung cancer trials. Read more to see why I'm bullish on ITOS ...

The combination did not benefit a biomarker unselected population, but those with mismatch repair-deficient tumors had extended disease-free survival.